UniQure (QURE) said Thursday its experimental gene therapy, AMT-130, received breakthrough therapy designation from the US Food and Drug Administration for the treatment of Huntington's disease, a neurodegenerative disorder, sending shares up nearly 35% in premarket activity.
The company said the decision is based on interim data from an ongoing phase I/II trial, which showed that AMT-130 may slow disease progression in a dose-dependent manner.
The new designation adds to the therapy's existing regenerative medicine advanced therapy designation, orphan drug designation, and fast-track designation, it added.
Breakthrough therapy designation speeds up the development and review of treatments showing early signs of significant benefit for severe conditions.
The company said it expects to deliver an additional regulatory update and guidance on the Biologics License Application submission in the second quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。